Followers | 2775 |
Posts | 77901 |
Boards Moderated | 1 |
Alias Born | 05/10/2007 |
Thursday, February 11, 2016 12:37:07 AM
On June 15, 2015, we and Bayer entered into a License and Development Agreement ( the “Agreement”) granting Bayer an exclusive worldwide license to our Impede Technology for use in an undisclosed methamphetamine resistant pseudoephedrine –containing product (the “Bayer Licensed Product”) and providing for the joint development of such product utilizing our Impede Technology for the U.S. market. The Agreement also grants Bayer first right to negotiate a license to the Impede technology for certain other products.
We and Bayer have formed a joint development committee to coordinate development of the Bayer Licensed Product. We will be eligible to receive reimbursement of certain of our development costs, success-based development and regulatory milestones payments, and low mid-single digit royalties on net sales of the Bayer Licensed product in countries with patent coverage and a reduced royalty elsewhere.
The term of the Agreement with respect to each country expires when royalties are no longer payable with respect to such country. After expiration of the term Bayer retains a license to sell the Bayer Licensed Product on a royalty free basis. Either party may terminate the Agreement in its entirety if the other party materially breaches the Agreement, subject to an applicable cure period, or in the event the other party makes an assignment for the benefit of creditors, files a petition in bankruptcy or otherwise seeks relief under applicable bankruptcy laws. Bayer may terminate the Agreement immediately prior to completion of our development obligations or at any time upon six (6) months prior written notice thereafter. We may terminate the Agreement with respect to the U.S. if Bayer ceases or suspends development or commercialization of the Bayer Licensed Product for a certain period of time.
Recent ACUR News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 03:53:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 03:27:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 10:13:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 08:23:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 08:23:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 08:20:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 08:20:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 05:01:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 07:35:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/20/2023 05:08:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/20/2023 05:08:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/20/2023 05:07:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/20/2023 05:07:02 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/03/2023 04:42:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 04:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2023 08:10:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 11:00:22 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/31/2023 08:10:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2023 08:10:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2023 03:20:22 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/10/2023 04:17:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/28/2023 08:41:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/28/2023 03:50:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 01:00:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2023 06:04:11 PM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM